Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds

by Benzinga Staff
September 26, 2012 8:01 AM | 12 seconds read | Make a Comment

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceuticalcompany commercializing potential best in class oncology and CNS therapeutics,today announced that the European Patent Office has granted European patentNo. 2099765 to Rexahn, entitled “5, 6, or 7-Substituted-3-arylisoquinolinaminederivatives as antitumor agents.”

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDAGlobal

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.